Highest-materiality recent filing
Authorized common shares increased from 18.75M to 60M (pre-split) via Certificate of Amendment, approved at June 25 annual meeting.
SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M
Effective May 29, 2026, every 8 outstanding shares converted into 1 share; par value stays $0.001.
SCYNEXIS stockholders approve 1-for-8 reverse stock split; effective May 29
Reverse stock split approved at 1:8 ratio; authorized shares reduced from 150M to 18.75M.
Director Steven C. Gilman to retire from SCYNEXIS Board at 2026 annual meeting
Steven C. Gilman notified SCYNEXIS Board on April 16, 2026 of intent to retire and not stand for reelection.
SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total
Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.
SCYNEXIS raises ~$40M in private placement; extends cash runway into mid-2029
Gross proceeds of ~$40M from sale of 34.75M shares and 8.75M pre-funded warrants at $0.92 per unit; up to $52.2M additional if warrants exercised.
SCYNEXIS discusses asset acquisition in corporate update call
Conference call held on March 31, 2026 covering an asset acquisition transaction.
SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment
Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.
SCYNEXIS stockholders re-elect all seven directors, ratify Deloitte, approve say-on-pay at 2025 AGM
All seven director nominees elected with >13M votes for each; broker non-votes ~12.5M.
SCYNEXIS receives Nasdaq bid price deficiency notice; has until Dec 17 to regain compliance
Received Nasdaq letter on June 20, 2025, for bid price <$1 for 30 consecutive business days.
SCYNEXIS enters $50M at-the-market equity facility with Cantor Fitzgerald
New Sales Agreement with Cantor allows sale of up to $50M of common stock at SCYNEXIS's option.
SCYNEXIS updates corporate presentation; no material new details disclosed
Filed 8-K on Sept 10, 2024 to announce updated investor slide deck.
All seven director nominees elected with 93.6%-96.7% of votes cast in favor.
Net income of $67.0M ($1.40 basic EPS) vs net loss of $62.8M in FY2022; license revenue of $139M vs $103K prior year.
SCYNEXIS updates corporate presentation; no material new disclosures
Company posted an updated investor slide presentation on its website on Jan. 5, 2024.
SCYNEXIS amends GSK license after BREXAFEMME recall; milestone payments cut
Binding MOU amends March 2023 license after beta-lactam contamination risk triggered BREXAFEMME recall and clinical hold.
SCYNEXIS recalls BREXAFEMME; FDA places clinical hold after cross-contamination risk
Recall of BREXAFEMME (ibrexafungerp) initiated Sep 25, 2023 due to potential cross-contamination during manufacture.
SCYNEXIS recalls BREXAFEMME and pauses Phase 3 MARIO study on cross-contamination risk
GSK review found a beta-lactam drug manufactured on equipment shared with ibrexafungerp; potential cross-contamination risk.
Terminated $35M Loan and Security Agreement with Hercules Capital and SVB on May 25, 2023, after receiving upfront payment from GSK license.
SCYNEXIS shareholders reject officer liability limit; approve equity plans
Proposal to amend certificate to limit officer liability failed (12.98M for, 4.07M against, needed majority of 36.5M outstanding shares).
SCYNEXIS licenses ibrexafungerp to GSK for $90M upfront plus up to $503M milestones
Upfront payment of $90M; eligible for up to $70M regulatory, $115M commercial, $242.5M sales, and $75.5M development milestones.
SCYNEXIS Q3 net loss $29.6M ($0.62/sh), BREXAFEMME rev $1.6M; CEO to retire; PDUFA Nov 30
Q3 2022 net loss $29.6M vs $0.6M loss in Q3 2021; basic loss per share $0.62 vs $0.02.
SCYNEXIS CEO to retire Dec 31; appoints new CEO David Angulo and CFO Ivor Macleod
CEO Marco Taglietti to retire Dec 31, 2022; separation extends stock option exercise period to 4 years.
SCYNEXIS shareholders approve doubling authorized common shares to 150M
Shareholders voted to increase authorized common stock from 100M to 150M shares.
SCYNEXIS Q2 net loss $13.3M, revenue $1.3M; cash runway into Q1 2024
BREXAFEMME net revenue $1.3M in Q2 2022, up 86% from $0.7M in Q1.
SCYNEXIS shareholders reject proposal to increase authorized shares from 100M to 150M
All seven director nominees elected; auditor Deloitte & Touche ratified.
SCYNEXIS Q1 net loss $5.5M; BREXAFEMME sales $0.7M; CANDLE study positive for rVVC
Net loss $5.5M ($0.17/share) vs $4.7M ($0.18) in Q1 2021; product revenue $0.7M from BREXAFEMME.
SCYNEXIS announces $41.9M public offering of common stock and warrants
Offering of 3,333,333 shares, pre-funded warrants for 11,666,667 shares, and warrants for 15,000,000 shares at $3.00 per share.
SCYNEXIS reports 2021 net loss of $32.9M; BREXAFEMME revenues $1.1M in launch year
BREXAFEMME net product revenue $1.1M full-year, $0.6M Q4; cost of product revenue $0.3M full-year.
SCYNEXIS receives $5M third tranche from Hercules/SVB Term Loan after CANDLE milestone
On March 9, 2022, SCYNEXIS drew $5M under its existing $60M Term Loan with Hercules/SVB.
CEO Marco Taglietti receives 87,200 RSUs and options for 232,000 shares at $4.60 per share.
SCYNEXIS reports Q3 net loss $0.6M; BREXAFEMME net sales $0.5M in first partial quarter
BREXAFEMME net sales $0.5M in partial Q3; IQVIA 1,006 prescriptions in Q3, 1,100 in October.
SCYNEXIS CFO Eric Francois to resign; Lawrence Hoffman appointed interim CFO effective Nov 19, 2021
CFO Eric Francois to resign effective Nov 19, 2021 to return to investment banking; will stay through transition.
SCYNEXIS CFO Eric Francois resigns; Danforth Advisors to provide interim CFO
Chief Financial Officer Eric Francois notified resignation on Oct 26, 2021, effective Nov 19, 2021, to return to investment banking.
On October 20, 2022, SCYNEXIS announced that David Angulo, M.D., SCYNEXIS’s Chief Medical Officer, will become SCYNEXIS’s President and Chief Executive Officer and become a member of the Board of Directors effective January 1, 2023.
On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.
On October 20, 2022, SCYNEXIS announced that Ivor Macleod, CPA, MBA, will become SCYNEXIS’s Chief Financial Officer, in which role he will become SCYNEXIS’s principal financial officer and principal accounting officer. Mr. Macleod’s anticipated first date of employment is October 24, 2022.
On November 1, 2021, the Board of Directors of SCYNEXIS appointed Lawrence Hoffman, CPA, ESQ, of Danforth Advisors, LLC (“Danforth”) as interim Chief Financial Officer, effective as of the Transition Date.
As previously announced, Eric Francois, Chief Financial Officer of SCYNEXIS, Inc. (the “Company”), will resign to return to his prior career in investment banking.
On October 26, 2021, Eric Francois, Chief Financial Officer of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to resign to return to his prior career in investment banking.
Max materiality 0.90 · Median 0.60 · Most common event other_material